DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the market capitalisation of Earkart Limited?

Earkart Limited has a market capitalisation of approximately ₹220 crore.

Earkart Limited

EARKARTLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Medical Equipment

A steady, established business

52W₹104

₹266-65%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹220 Cr

P/E Ratio

N/A

P/B Ratio

3.40

EPS

₹6.59

Book Value

₹47.02

ROE

11.70%Average

ROCE

45.13%Efficient

Dividend Yield

0.00%

Debt / Equity

0.00Low

Face Value

₹10.00

52W High

₹265.95

52W Low

₹104.35

Sector

Healthcare

Industry

Medical Equipment

Fairly Valued

Narrow moatHigh uncertainty

Fair value estimate

₹111

No recent traded price

BearFair valueBull

₹62₹111₹127

/100

Business quality — Solid

Growth 50Profitability 56Efficiency 100Valuation 100

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 45%)
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

35% ROE fading to 12% over ~10 yrs, on ₹47 book

₹124

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹62

Analyst target

No analyst coverage

—

Blended fair value₹111

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 45%)
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

—

ROE

11.7%Average

Above 15% is considered healthy for Indian equities

ROCE

45.1%Efficient

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹220 Cr

P/B

3.40

EPS

₹6.59

Div Yield

—

What changed

Recent changes

Foreign investors-5.1% stake last quarter
Domestic institutions+9.3% stake last quarter

What matters

News impact

Overview

Valuation

N/A

No P/E

Growth

Strong

+23% rev CAGR

Profitability

Modest

11.7% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+23.2%

—

10Y

—

Profit

+60.7%

—

10Y

—

EPS

-76.1%

—

10Y

—

Profile

Pros

Company has reduced debt.
Company is almost debt free.

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Working capital days have increased from 161 days to 237 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 5.14 pts; domestic institutions added 9.34 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

57%

Promoter

Promoters

57.3%0.00

Public

16.9%-3.86

FII / FPI

0.0%-5.14

DII

21.9%+9.34

Others

3.8%

Total shareholders

240-290 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter57.34%

DII21.95%

Public16.94%

Others3.77%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Earkart Limited valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

Earkart Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare Earkart Limited with peers

Earkart Limited vs SUN PHARMACEUTICAL IND L Earkart Limited vs DIVI S LABORATORIES LTD Earkart Limited vs TORRENT PHARMACEUTICALS L Earkart Limited vs APOLLO HOSPITALS ENTER. L Earkart Limited vs ZYDUS LIFESCIENCES LTD Earkart Limited vs CIPLA LTD

Earkart Limited

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

Earkart Limited valuation & research

Earkart Limited peers in Healthcare

Compare Earkart Limited with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions